MedTrace Logo

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

NCT03028766 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-09-19

No results posted yet for this study

Summary

This trial is to determine what dose of a drug called AZD1775 can safely be given in combination with cisplatin before surgery and with chemo-radiotherapy after surgery in patients with Head and Neck Cancer. The Investigators will also get some preliminary information regarding the effectiveness of this combined treatment.

Conditions

  • Hypopharynx Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma
  • Larynx Cancer

Interventions

DRUG

AZD1775

AZD1775 is a potent, selective small molecule inhibitor of WEE1

DRUG

Cisplatin

Chemotherapy drug

RADIATION

Radiotherapy

Intensity Modulated Radiotherapy

Sponsors & Collaborators

Principal Investigators

  • Hisham Mehanna · University of Birmingham

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-22
Primary Completion
2019-10-31
Completion
2021-02-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03028766 on ClinicalTrials.gov